You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 155 No. 15, 7 AUGUST 1995 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Investigations
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (62)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Clinical Features, Site of Involvement, Bacteriologic Findings, and Outcome of Infective Endocarditis in Intravenous Drug Users

James Mathew, MD; Theodore Addai, MD; Ashwin Anand, MD; Angel Morrobel, MD; Pradeep Maheshwari, MD; Sally Freels, PhD

Arch Intern Med. 1995;155(15):1641-1648.


Abstract

Background
Intravenous drug use is an increasingly common condition predisposing to infective endocarditis. Data on infective endocarditis in intravenous drug users are limited.

Objective
To determine the clinical features, bacteriologic findings, site of involvement, complications, and mortality associated with infective endocarditis in intravenous drug users.

Methods
Cohort study of intravenous drug users with native valve infective endocarditis.

Results
A total of 125 cases of infective endocarditis occurred in 114 patients (84 cases [67%] in men and 41 cases [32%] in women) with a mean (±SD) age of 37±7 years. The tricuspid valve was involved in 58 cases (46%), the mitral valve in 40 cases (32%), and the aortic valve in 24 cases (19%). The microorganisms identified included Staphylococcus in 82 cases (65.6%) and Streptococcus in 32 cases (25.6%). Twenty-three patients (18%) underwent surgery, and two (9%) of them died. One hundred two patients (82%) were treated medically, and nine (9%) of them died. Fifteen patients (63%) with aortic valve involvement vs 17 patients (17%) without aortic valve involvement underwent surgery or died without surgery (odds ratio, 8.24; 95% confidence interval, 3.1 to 21.8). Among the survivors, at least one major cardiovascular complication occurred in 79 cases (69.3%).

Conclusions
Infective endocarditis in intravenous drug users affects the right and left sides of the heart with approximately equal frequency. At present, more than 90% of cases of infective endocarditis in intravenous drug users in Chicago are caused by staphylococci or streptococci. Involvement of the aortic valve is predictive of increased morbidity and mortality in intravenous drug users with infective endocarditis. With medical treatment, and surgery when medical treatment fails, intravenous drug users with infective endocarditis have an in-hospital survival rate of 91%.

(Arch Intern Med. 1995;155:1641-1648)



Author Affiliations

From the Division of Adult Cardiology, Department of Medicine, Cook County Hospital, Chicago, Ill (Drs Mathew, Addai, Anand, Morrobel, and Maheshwari); the Department of Medicine, University of Illinois at Chicago (Dr Mathew); and the Department of Biostatistics, School of Public Health, University of Chicago (Dr Freels).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC)
Endorsed by the European Society of Clinical Micro et al.
Eur Heart J 2009;30:2369-2413.
FULL TEXT  

Infective endocarditis from injecting heroin into a leg ulcer
Thakor and Wijenaike
BMJ Case Reports 2009;2009:bcr0720080493-bcr0720080493.
FULL TEXT  

Multiple Valve Disease
Schaff and Suri
Card Surg Adult 2008;3:1129-1158.
FULL TEXT  

Impact of Empirical-Therapy Selection on Outcomes of Intravenous Drug Users with Infective Endocarditis Caused by Methicillin-Susceptible Staphylococcus aureus
Lodise et al.
Antimicrob. Agents Chemother. 2007;51:3731-3733.
ABSTRACT | FULL TEXT  

Myocardial infarction in young adults
Egred et al.
Postgrad. Med. J. 2005;81:741-745.
ABSTRACT | FULL TEXT  

Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America
Baddour et al.
Circulation 2005;111:e394-e434.
ABSTRACT | FULL TEXT  

Molecular Diagnosis of Infective Endocarditis: A Helpful Addition to the Duke Criteria
Tak and Shukla
Clin Med Res 2004;2:206-208.
FULL TEXT  

Long-term results after cardiac surgery in patients infected with the human immunodeficiency virus type-1 (HIV-1)
Mestres et al.
Eur. J. Cardiothorac. Surg. 2003;23:1007-1016.
ABSTRACT | FULL TEXT  

Injection drug use and right sided endocarditis
Moss and Munt
Heart 2003;89:577-581.
FULL TEXT  

Acute myocardial infarction in young adults: causes and management
Osula et al.
Postgrad. Med. J. 2002;78:27-30.
ABSTRACT | FULL TEXT  

Value of Echocardiographic Findings in Predicting Cardiovascular Complications in Infective Endocarditis
Mathew et al.
ANGIOLOGY 2001;52:801-809.
ABSTRACT  

Primary Chylopericardium in a Heroin Addict
Chello et al.
Asian Cardiovasc. Thorac. Ann. 1998;6:235-236.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.